Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PET Drugs May Get Shorter Path To FDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

For positron emission tomography drugs with low levels of use that are needed to diagnose rare conditions, an expanded access IND may be the best regulatory pathway.
Advertisement

Related Content

PET Drugs Without An IND Get Three More Years For Studies Under FDA Guidance
FluoroPharma’s Bet On Next-Gen Molecular Imaging Agents
PET Drug Research Still In FDA's Enforcement Crosshairs As Columbia University Draws Warning Letter
Swedish Orphan, Under Pressure At Home, Looks to Commerical Swap With China Company For Growth
FDA Develops Separate Set Of GMP Requirements For PET Drug Makers
FDA Develops Separate Set Of GMP Requirements For PET Drug Makers

Topics

Advertisement
UsernamePublicRestriction

Register

PS072030

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel